Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 250

1.

Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis.

Richeldi L, Kolb M, Jouneau S, Wuyts WA, Schinzel B, Stowasser S, Quaresma M, Raghu G.

BMC Pulm Med. 2020 Jan 8;20(1):3. doi: 10.1186/s12890-019-1030-4.

2.

Twenty-five years of Respirology: Advances in idiopathic pulmonary fibrosis.

Varone F, Inoue Y, Richeldi L.

Respirology. 2020 Jan;25(1):20-22. doi: 10.1111/resp.13733. Review. No abstract available.

3.

Neuropsychiatric reactions induced by cycloserine in the treatment of multidrug-resistant tuberculosis: what an Indian female patient tells us.

Intini E, Kishore G, Richeldi L, Udwadia ZF.

BMJ Case Rep. 2019 Dec 4;12(12). pii: e230993. doi: 10.1136/bcr-2019-230993.

PMID:
31806629
4.

Alemtuzumab-induced lung injury in multiple sclerosis: Learning from adversity in three patients.

Bianco A, Mari PV, Larici AR, Lucchini M, Nociti V, Losavio FA, De Fino C, Cicchetti G, Coraci D, Richeldi L, Mirabella M.

Mult Scler Relat Disord. 2019 Oct 15;37:101450. doi: 10.1016/j.msard.2019.101450. [Epub ahead of print]

PMID:
31675637
5.

Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial.

Richeldi L, Fernández Pérez ER, Costabel U, Albera C, Lederer DJ, Flaherty KR, Ettinger N, Perez R, Scholand MB, Goldin J, Peony Yu KH, Neff T, Porter S, Zhong M, Gorina E, Kouchakji E, Raghu G.

Lancet Respir Med. 2020 Jan;8(1):25-33. doi: 10.1016/S2213-2600(19)30262-0. Epub 2019 Sep 28.

PMID:
31575509
6.

Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.

Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, Richeldi L, Kolb M, Tetzlaff K, Stowasser S, Coeck C, Clerisme-Beaty E, Rosenstock B, Quaresma M, Haeufel T, Goeldner RG, Schlenker-Herceg R, Brown KK; INBUILD Trial Investigators.

N Engl J Med. 2019 Oct 31;381(18):1718-1727. doi: 10.1056/NEJMoa1908681. Epub 2019 Sep 29.

PMID:
31566307
7.

The 2018 Diagnosis of Idiopathic Pulmonary Fibrosis Guidelines: Surgical Lung Biopsy for Radiological Pattern of Probable Usual Interstitial Pneumonia Is Not Mandatory.

Raghu G, Remy-Jardin M, Myers J, Richeldi L, Wilson KC.

Am J Respir Crit Care Med. 2019 Nov 1;200(9):1089-1092. doi: 10.1164/rccm.201907-1324ED. No abstract available.

8.

Which Biopsy to Diagnose Interstitial Lung Disease? A Call for Evidence and Unity.

Richeldi L, Cottin V, Brown KK, Flaherty KR, Johannson KA, Travis WD, Collard HR.

Am J Respir Crit Care Med. 2019 Oct 1;200(7):941-942. doi: 10.1164/rccm.201905-0932LE. No abstract available.

9.

Outcomes following decline in forced vital capacity in patients with idiopathic pulmonary fibrosis: Results from the INPULSIS and INPULSIS-ON trials of nintedanib.

Richeldi L, Crestani B, Azuma A, Kolb M, Selman M, Stansen W, Quaresma M, Stowasser S, Cottin V.

Respir Med. 2019 Sep;156:20-25. doi: 10.1016/j.rmed.2019.08.002. Epub 2019 Aug 6.

PMID:
31404749
10.

Autophagy inhibition-mediated epithelial-mesenchymal transition augments local myofibroblast differentiation in pulmonary fibrosis.

Hill C, Li J, Liu D, Conforti F, Brereton CJ, Yao L, Zhou Y, Alzetani A, Chee SJ, Marshall BG, Fletcher SV, Hancock D, Ottensmeier CH, Steele AJ, Downward J, Richeldi L, Lu X, Davies DE, Jones MG, Wang Y.

Cell Death Dis. 2019 Aug 7;10(8):591. doi: 10.1038/s41419-019-1820-x.

11.

Evaluation of the lung microbiome as a therapeutic target in the management of idiopathic pulmonary fibrosis: role of antioxidant/antibiotic combination therapy.

Varone F, Gibiino G, Gasbarrini A, Richeldi L.

Eur Rev Med Pharmacol Sci. 2019 Jul;23(14):6379-6386. doi: 10.26355/eurrev_201907_18463.

12.

Demystifying fibrotic hypersensitivity pneumonitis diagnosis: it's all about shades of grey.

Walsh SLF, Richeldi L.

Eur Respir J. 2019 Jul 25;54(1). pii: 1900906. doi: 10.1183/13993003.00906-2019. Print 2019 Jul. No abstract available.

PMID:
31345989
13.

Statin Therapy and Lung Disorders.

Mari PV, Lombardi F, Flore MC, Richeldi L.

Am J Respir Crit Care Med. 2019 Oct 1;200(7):921-923. doi: 10.1164/rccm.201804-0725RR. No abstract available.

PMID:
31247147
14.

Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis.

Walsh SLF, Lederer DJ, Ryerson CJ, Kolb M, Maher TM, Nusser R, Poletti V, Richeldi L, Vancheri C, Wilsher ML, Antoniou KM, Behr J, Bendstrup E, Brown KK, Corte TJ, Cottin V, Crestani B, Flaherty KR, Glaspole IN, Grutters J, Inoue Y, Kondoh Y, Kreuter M, Johannson KA, Ley B, Martinez FJ, Molina-Molina M, Morais A, Nunes H, Raghu G, Selman M, Spagnolo P, Taniguchi H, Tomassetti S, Valeyre D, Wijsenbeek M, Wuyts WA, Wells AU.

Am J Respir Crit Care Med. 2019 Nov 1;200(9):1146-1153. doi: 10.1164/rccm.201903-0493OC.

15.

Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials.

Lancaster L, Crestani B, Hernandez P, Inoue Y, Wachtlin D, Loaiza L, Quaresma M, Stowasser S, Richeldi L.

BMJ Open Respir Res. 2019 Mar 25;6(1):e000397. doi: 10.1136/bmjresp-2018-000397. eCollection 2019.

16.

Digital Lung Auscultation: Will Early Diagnosis of Fibrotic Interstitial Lung Disease Become a Reality?

Richeldi L, Cottin V, Würtemberger G, Kreuter M, Calvello M, Sgalla G.

Am J Respir Crit Care Med. 2019 Jul 15;200(2):261-263. doi: 10.1164/rccm.201902-0306LE. No abstract available.

PMID:
31150267
17.

X-ray Micro-Computed Tomography for Nondestructive Three-Dimensional (3D) X-ray Histology.

Katsamenis OL, Olding M, Warner JA, Chatelet DS, Jones MG, Sgalla G, Smit B, Larkin OJ, Haig I, Richeldi L, Sinclair I, Lackie PM, Schneider P.

Am J Pathol. 2019 Aug;189(8):1608-1620. doi: 10.1016/j.ajpath.2019.05.004. Epub 2019 May 22.

18.

The Ariane-IPF ERS Clinical Research Collaboration: seeking collaboration through launch of a federation of European registries on idiopathic pulmonary fibrosis.

Cottin V, Annesi-Maesano I, Günther A, Galvin L, Kreuter M, Powell P, Prasse A, Reynolds G, Richeldi L, Spagnolo P, Valenzuela C, Wijsenbeek M, Wuyts WA, Crestani B; Ariane-IPF Clinical Research Collaboration consortium.

Eur Respir J. 2019 May 23;53(5). pii: 1900539. doi: 10.1183/13993003.00539-2019. Print 2019 May. No abstract available.

PMID:
31123022
19.

Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study.

Raghu G, van den Blink B, Hamblin MJ, Brown AW, Golden JA, Ho LA, Wijsenbeek MS, Vasakova M, Pesci A, Antin-Ozerkis DE, Meyer KC, Kreuter M, Moran D, Santin-Janin H, Aubin F, Mulder GJ, Gupta R, Richeldi L.

Lancet Respir Med. 2019 Aug;7(8):657-664. doi: 10.1016/S2213-2600(19)30172-9. Epub 2019 May 20.

PMID:
31122893
20.

Contemporary Concise Review 2018: Interstitial lung disease.

Mari PV, G Jones M, Richeldi L.

Respirology. 2019 Aug;24(8):809-816. doi: 10.1111/resp.13572. Epub 2019 May 8. Review. No abstract available.

21.

Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage.

Ryerson CJ, Kolb M, Richeldi L, Lee J, Wachtlin D, Stowasser S, Poletti V.

ERJ Open Res. 2019 Apr 29;5(2). pii: 00127-2018. doi: 10.1183/23120541.00127-2018. eCollection 2019 Apr.

22.

Update in Pulmonary Fibrosis 2018.

Sgalla G, Kulkarni T, Antin-Ozerkis D, Thannickal VJ, Richeldi L.

Am J Respir Crit Care Med. 2019 Aug 1;200(3):292-300. doi: 10.1164/rccm.201903-0542UP. No abstract available.

PMID:
31022351
23.

The Fibrosis Across Organs Symposium: A Roadmap for Future Research Priorities.

Roman J, Barnes TR, Kervitsky DJ, Cosgrove GP, Doherty DE, Tager AM, Richeldi L, White ES, Brenner DA, Schnapp LM, Hewitson TD, Jugdutt BI, McKinsey TA, Tosi JD, Crane S, Brown KK; Fibrosis Across Organs Symposium Working Group.

Am J Med Sci. 2019 May;357(5):405-410. doi: 10.1016/j.amjms.2019.02.014. No abstract available.

24.

Current and Future Idiopathic Pulmonary Fibrosis Therapy.

Richeldi L, Baldi F, Pasciuto G, Macagno F, Panico L.

Am J Med Sci. 2019 May;357(5):370-373. doi: 10.1016/j.amjms.2019.02.006. Epub 2019 Feb 11. Review.

PMID:
31010462
25.

Impact of chest imaging quality on the diagnosis of the usual interstitial pneumonia pattern: a hub and spoke study.

Sgalla G, Larici AR, Re A, Farchione A, Cicchetti G, Calandriello L, Comes A, Golfi N, Iovene B, Varone F, Manfredi R, Richeldi L.

Eur Respir J. 2019 Jun 27;53(6). pii: 1900084. doi: 10.1183/13993003.00084-2019. Print 2019 Jun. No abstract available.

PMID:
31000672
26.

Design of Idiopathic Pulmonary Fibrosis Clinical Trials in the Era of Approved Therapies.

Kaner RJ, Bajwa EK, El-Amine M, Gorina E, Gupta R, Lazarus HM, Luckhardt TR, Mouded M, Posada K, Richeldi L, Stauffer J, Tutuncu A, Martinez FJ.

Am J Respir Crit Care Med. 2019 Jul 15;200(2):133-139. doi: 10.1164/rccm.201903-0592PP. No abstract available.

PMID:
30985215
27.

Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSIS® trials.

Kreuter M, Koegler H, Trampisch M, Geier S, Richeldi L.

Respir Res. 2019 Apr 11;20(1):71. doi: 10.1186/s12931-019-1037-7.

28.

The characterisation of interstitial lung disease multidisciplinary team meetings: a global study.

Richeldi L, Launders N, Martinez F, Walsh SLF, Myers J, Wang B, Jones M, Chisholm A, Flaherty KR.

ERJ Open Res. 2019 Apr 1;5(2). pii: 00209-2018. doi: 10.1183/23120541.00209-2018. eCollection 2019 Apr.

29.

Agreement between chest ultrasonography and chest X-ray in patients who have undergone thoracic surgery: preliminary results.

Smargiassi A, Inchingolo R, Chiappetta M, Ciavarella LP, Lopatriello S, Corbo GM, Margaritora S, Richeldi L.

Multidiscip Respir Med. 2019 Mar 4;14:9. doi: 10.1186/s40248-019-0171-x. eCollection 2019.

30.

New Frontiers in Ultrasonography of the Mediastinum: Pediatric EBUS-TBNA.

Fuso L, Varone F, Magnini D, Calvello M, Lo Greco E, Richeldi L.

Respir Care. 2019 Mar;64(3):358-359. doi: 10.4187/respcare.06831. No abstract available.

PMID:
30850556
31.

Educational interventions alone and combined with port protector reduce the rate of central venous catheter infection and colonization in respiratory semi-intensive care unit.

Inchingolo R, Pasciuto G, Magnini D, Cavalletti M, Scoppettuolo G, Montemurro G, Smargiassi A, Torelli R, Sanguinetti M, Spanu T, Corbo GM, Richeldi L.

BMC Infect Dis. 2019 Mar 4;19(1):215. doi: 10.1186/s12879-019-3848-z.

32.

Subclinical Interstitial Lung Abnormalities: Lumping and Splitting Revisited.

Walsh SLF, Richeldi L.

Am J Respir Crit Care Med. 2019 Jul 15;200(2):121-123. doi: 10.1164/rccm.201901-0180ED. No abstract available.

33.

Lung function outcomes in the INPULSIS® trials of nintedanib in idiopathic pulmonary fibrosis.

Brown KK, Flaherty KR, Cottin V, Raghu G, Inoue Y, Azuma A, Huggins JT, Richeldi L, Stowasser S, Stansen W, Schlenker-Herceg R, Maher TM, Wells AU.

Respir Med. 2019 Jan;146:42-48. doi: 10.1016/j.rmed.2018.11.012. Epub 2018 Nov 19.

34.

Quantitative analysis of lung sounds for monitoring idiopathic pulmonary fibrosis: a prospective pilot study.

Sgalla G, Larici AR, Sverzellati N, Bartholmai B, Walsh SLF, Nikolic D, Barney A, Fletcher S, Jones M, Davies DD, Richeldi L.

Eur Respir J. 2019 Mar 7;53(3). pii: 1802093. doi: 10.1183/13993003.02093-2018. Print 2019 Mar. No abstract available.

PMID:
30578384
35.

Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence.

Richeldi L, Varone F, Bergna M, de Andrade J, Falk J, Hallowell R, Jouneau S, Kondoh Y, Morrow L, Randerath W, Strek M, Tabaj G.

Eur Respir Rev. 2018 Dec 21;27(150). pii: 180074. doi: 10.1183/16000617.0074-2018. Print 2018 Dec 31. Review.

36.

Reply to Moodley and to Ravaglia et al.

Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Wilson K.

Am J Respir Crit Care Med. 2019 Mar 1;199(5):667-669. doi: 10.1164/rccm.201810-2006LE. No abstract available.

PMID:
30566844
37.

Idiopathic Pulmonary Fibrosis: Prospective, Case-Controlled Study of Natural History and Circulating Biomarkers.

Raghu G, Richeldi L, Jagerschmidt A, Martin V, Subramaniam A, Ozoux ML, Esperet CA, Soubrane C.

Chest. 2018 Dec;154(6):1359-1370. doi: 10.1016/j.chest.2018.08.1083.

PMID:
30526970
38.

Existing and emerging biomarkers for disease progression in idiopathic pulmonary fibrosis.

Inchingolo R, Varone F, Sgalla G, Richeldi L.

Expert Rev Respir Med. 2019 Jan;13(1):39-51. doi: 10.1080/17476348.2019.1553620. Epub 2018 Dec 17. Review.

PMID:
30526140
39.

No relevant pharmacokinetic drug-drug interaction between nintedanib and pirfenidone.

Richeldi L, Fletcher S, Adamali H, Chaudhuri N, Wiebe S, Wind S, Hohl K, Baker A, Schlenker-Herceg R, Stowasser S, Maher TM.

Eur Respir J. 2019 Jan 10;53(1). pii: 1801060. doi: 10.1183/13993003.01060-2018. Print 2019 Jan.

PMID:
30442716
40.

Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice.

Fletcher SV, Jones MG, Renzoni EA, Parfrey H, Hoyles RK, Spinks K, Kokosi M, Kwok A, Warburton C, Titmuss V, Thillai M, Simler N, Maher TM, Brereton CJ, Chua F, Wells AU, Richeldi L, Spencer LG.

ERJ Open Res. 2018 Oct 19;4(4). pii: 00049-2018. doi: 10.1183/23120541.00049-2018. eCollection 2018 Oct.

41.

Alpha-1 antitrypsin deficiency as a common treatable mechanism in chronic respiratory disorders and for conditions different from pulmonary emphysema? A commentary on the new European Respiratory Society statement.

Gramegna A, Aliberti S, Confalonieri M, Corsico A, Richeldi L, Vancheri C, Blasi F.

Multidiscip Respir Med. 2018 Oct 8;13:39. doi: 10.1186/s40248-018-0153-4. eCollection 2018.

42.

SAR156597 in idiopathic pulmonary fibrosis: a phase 2 placebo-controlled study (DRI11772).

Raghu G, Richeldi L, Crestani B, Wung P, Bejuit R, Esperet C, Antoni C, Soubrane C.

Eur Respir J. 2018 Dec 13;52(6). pii: 1801130. doi: 10.1183/13993003.01130-2018. Print 2018 Dec.

PMID:
30337444
43.

Molecular Testing in EBUS-TBNA Specimens of Lung Adenocarcinoma: A Study of Concordance Between Cell Block Method and Liquid-Based Cytology in Appraising Sample Cellularity and EGFR Mutations.

Magnini D, Fuso L, Varone F, D'Argento E, Martini M, Pecoriello A, Di Noia V, Arciuolo D, Fadda G, Rindi G, Richeldi L.

Mol Diagn Ther. 2018 Dec;22(6):723-728. doi: 10.1007/s40291-018-0359-3.

PMID:
30276554
44.

Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis.

Kolb M, Raghu G, Wells AU, Behr J, Richeldi L, Schinzel B, Quaresma M, Stowasser S, Martinez FJ; INSTAGE Investigators.

N Engl J Med. 2018 Nov 1;379(18):1722-1731. doi: 10.1056/NEJMoa1811737. Epub 2018 Sep 15.

PMID:
30220235
45.

Diagnosing idiopathic pulmonary fibrosis in 2018: bridging recommendations made by experts serving different societies.

Richeldi L, Wilson KC, Raghu G.

Eur Respir J. 2018 Sep 6;52(3). pii: 1801485. doi: 10.1183/13993003.01485-2018. Print 2018 Sep. No abstract available.

PMID:
30190265
46.

Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.

Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, Behr J, Cottin V, Danoff SK, Morell F, Flaherty KR, Wells A, Martinez FJ, Azuma A, Bice TJ, Bouros D, Brown KK, Collard HR, Duggal A, Galvin L, Inoue Y, Jenkins RG, Johkoh T, Kazerooni EA, Kitaichi M, Knight SL, Mansour G, Nicholson AG, Pipavath SNJ, Buendía-Roldán I, Selman M, Travis WD, Walsh S, Wilson KC; American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society.

Am J Respir Crit Care Med. 2018 Sep 1;198(5):e44-e68. doi: 10.1164/rccm.201807-1255ST.

PMID:
30168753
47.

Treating heart failure with preserved ejection fraction: learning from pulmonary fibrosis.

Graziani F, Varone F, Crea F, Richeldi L.

Eur J Heart Fail. 2018 Oct;20(10):1385-1391. doi: 10.1002/ejhf.1286. Epub 2018 Aug 7. Review.

48.

Ultrasonography of the Mediastinum: Techniques, Current Practice, and Future Directions.

Fuso L, Varone F, Magnini D, Calvello M, Lo Greco E, Richeldi L.

Respir Care. 2018 Nov;63(11):1421-1438. doi: 10.4187/respcare.06047. Epub 2018 Jul 31. Review.

49.

Paracrine signalling during ZEB1-mediated epithelial-mesenchymal transition augments local myofibroblast differentiation in lung fibrosis.

Yao L, Conforti F, Hill C, Bell J, Drawater L, Li J, Liu D, Xiong H, Alzetani A, Chee SJ, Marshall BG, Fletcher SV, Hancock D, Coldwell M, Yuan X, Ottensmeier CH, Downward J, Collins JE, Ewing RM, Richeldi L, Skipp P, Jones MG, Davies DE, Wang Y.

Cell Death Differ. 2019 May;26(5):943-957. doi: 10.1038/s41418-018-0175-7. Epub 2018 Jul 26.

50.

Reply to Rajchgot et al.: Combination Nintedanib and Pirfenidone for Treatment of Idiopathic Pulmonary Fibrosis.

Vancheri C, Kreuter M, Richeldi L, Quaresma M, Stowasser S, Wuyts WA.

Am J Respir Crit Care Med. 2018 Oct 15;198(8):1105-1106. doi: 10.1164/rccm.201806-1116LE. No abstract available.

PMID:
30025211

Supplemental Content

Loading ...
Support Center